GlassScriptPhysician profile
Sukh Dev Singh Khalsa
NPI 1881978682
$3,559.83
in general payments reported to CMS, 2019-2025
23 companies · $504 in 2025
The $504 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,389 · 2022: $1,534 · 2023: $77.50 · 2024: $55.45 · 2025: $504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $637.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $637.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $683.28 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $394.75 | 2021-2025 | Caplyta |
| Alkermes, INC. | $311.12 | 2021-2025 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $294.02 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $281.75 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $261.43 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $260.19 | 2021-2025 | |
| Bausch Health US, LLC | $229.44 | 2021-2025 | Aplenzin |
| Janssen Pharmaceuticals, INC | $158.55 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $137.59 | 2021-2023 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $126.75 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $73.56 | 2022 | |
| Noven Therapeutics, LLC | $69.10 | 2021-2025 | Xelstrym |
| Almatica Pharma LLC | $56.72 | 2022 | |
| Eisai INC. | $55.18 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $40.72 | 2021-2022 | |
| Corium, LLC | $22.58 | 2021 | |
| Jazz Pharmaceuticals INC. | $22.45 | 2022 | |
| Alfasigma USA, INC. | $20.28 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $17.50 | 2025 | Cobenfy |
| Adlon Therapeutics L.P. | $15.21 | 2021 | |
| Avanir Pharmaceuticals, INC. | $14.56 | 2022 | |
| Lundbeck LLC | $13.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sukh Dev Singh Khalsa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.